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The late Nobel Laureate Sir Peter Medawar once memorably described viruses as ‘bad news wrapped in protein’.
Virus assembly in HIV is a remarkably well coordinated process in which the virus achieves extracellular budding
using primarily intracellular budding machinery and also the unusual phenomenon of export from the cell of an
RNA. Recruitment of the ESCRT system by HIV is one of the best documented examples of the comprehensive way
in which a virus hijacks a normal cellular process. This review is a summary of our current understanding of the
budding process of HIV, from genomic RNA capture through budding and on to viral maturation, but centering on
the proteins of the ESCRT pathway and highlighting some recent advances in our understanding of the cellular
components involved and the complex interplay between the Gag protein and the genomic RNA.
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It is now over 20 years since the first striking pictures of a
failure in the terminal budding process of HIV were pub-
lished [1]. It took over three years for the findings to be
confirmed and validated [2], and this marked the begi-
nning of our understanding of the role of the ESCRT
(endosomal sorting complex required for transport) sys-
tem in the budding of HIV and subsequently in other
enveloped viruses. Insights gained from HIV have revealed
a wealth of details about normal cellular processes invol-
ving the ESCRT proteins, including vesicle budding into
endosomal compartments called multi-vesicular bodies
(MVB) [3] and the later discovery of the involvement of
this process in the terminal events of cell division and cell
separation [4]. How ESCRT functions in viral budding in
HIV is now understood in remarkable detail; however,
there are some notable unanswered questions.
Viral assembly is focused around the major structural
protein of the virus capsid - Gag - which is a 55 kDa
polyprotein comprising four major subdomains – Matrix
(MA), Capsid (CA), Nucleocapsid (NC) and p6. Flanking
NC are two small ‘spacer’ peptides SP1 (p2) and SP2
(p1). The assembly of capsid like particles in HIV and
other retroviruses can be achieved by the viral Gag pro-* Correspondence: amll1@medschl.cam.ac.uk
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[5], and indeed conical structures resembling mature
cores can also be formed [6,7], although production of
spherical particles is optimized by nucleic acid. Authen-
tic ‘extended’ Gag assemblies with dimensions compa-
rable to a wild type viral capsid can be formed in the
presence of lipid membranes and nucleic acid [8]. The
NC region of Gag is well established as contributing to
Gag assembly probably by ‘bridging’ between individual
Gag monomers via genomic RNA (gRNA) [9]. Assembly
of viable virus is possible using a minority of NC
mutated Gag proteins containing intact late domains
(see below) complemented by at least a fivefold excess of
Gags with intact NC domains containing a late domain
mutation [10], again inferring an important role for
RNA binding to the NC domain inducing bridging. Des-
pite the intimate interactions between Gag and RNA
preceding and following the virus assembly, RNA in ge-
neral and specifically the gRNA which is captured and
packaged specifically by the viral Gag protein appeared
until recently [11] to have no identified role in the
ESCRT mediated process of viral assembly. The second
conundrum is that whereas in MVB generation, sequen-
tial linking of ESCRT-0, I, II and III is essential, in HIV
budding it is still unclear how ESCRT-I activates
ESCRT-III given the apparent lack of requirement of
ESCRT-II for successful budding in HIV [12]. Thistral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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some striking in vitro assembly studies where ESCRT-II
does appear to be an integral part of the Gag budding
process [13].
This review is a summary of our current understanding
of the budding process of HIV, centering on the proteins
of the ESCRT pathway. However, although that is pro-
bably the most intensively investigated and documented
period in the virus export pathway, it is important to put
it in the context of the processes that precede and follow
it, but also overlap with it, namely trafficking and assem-
bly, and release and maturation.
Events preceding viral assembly and budding
The earliest cytoplasmic stages of viral nucleocapsid as-
sembly occur at the free cytoplasmic pool of translating
ribosomes where unspliced viral RNA is translated to pro-
duce Gag (Figure 1A), and a subpopulation of Gag/Pol
proteins are generated through a frameshift event. Gag is
translated from the RNA species that also functions as the
RNA genome. Once translated, the viral gRNA is traf-
ficked away from the translating pool [14]. Although
translation may not be a prerequisite for RNA capture
[15], subsequent data have reinforced a predominantly
cotranslational capture mechanism in HIV-1 [16,17] as
shown previously for HIV-2 [18]. The uncleaved Gag poly-
protein is involved in RNA genome capture, and the inter-
action of this with the viral RNA packaging signal [19,20]
has been shown in HIV-1 to be biophysically a very diffe-
rent process from that of interaction with the NC sub-
fragment of Gag [21]. The latter, however, after cleavage
from the precursor protein, is a powerful facilitator of nu-
cleic acid interactions such as those involved in genome
dimerization [22,23] and reverse transcription [24-27].
Following capture, evidence suggests that a small
number of Gag proteins accompany the gRNA to the
budding site at the plasma membrane [28-30]. Currently
there is still a relative paucity of knowledge regarding
the cellular components of the trafficking Gag/gRNA
nucleoprotein complex. UPF1 is suggested to be
involved in RNA stabilization [31] in association with
UPF3b and Staufen. The cellular ATPase ABCE1 is also
implicated in viral assembly in an RNA independent
manner [32] and together with DDX6 and other proces-
sing body proteins (PBP) facilitate Gag multimerization
[33]. The trafficking protein KIF-4 binds Gag [34], but
whether this is a requirement for Gag/gRNA complex
recruitment at the plasma membrane is unclear. Binding
to the clathrin associated adaptor proteins AP-2 and AP-3
has been documented [35,36]; however, the sequential in-
volvement of all these proteins in the Gag/gRNA nucleo-
protein complex during its trafficking through the cell is
still obscure. In Drosophila the RNA chaperone Staufen
and ESCRT proteins interact with RNA [37,38] andinfluence its directional subcellular trafficking. There is
also growing evidence that association of Gag with RNA is
important for the directional trafficking of the complex
[39]. Staufen has also been implicated in HIV-1 assembly
[40,41], but evidence of a close mechanistic link between
these factors in HIV-1 assembly is lacking.
Gag binds the viral RNA through interactions invol-
ving the NC domain of the polyprotein which itself con-
tributes specificity of RNA selection [42]. RNA also
binds non-specifically to a highly basic region of the MA
domain reducing non-specific binding to lipid mem-
branes [43] and increasing the specificity of MA for lipid
membranes containing phosphatidylinositol (4.5) di-
phosphate (PIP2) [8] such as the plasma membrane. A
saturated lipid myristic acid covalently linked to the
N-terminal region of Gag is sequestered in a hydropho-
bic pocket at the N terminus of MA and can be ejected
by pH changes [44], the so called ‘myristyl switch’ me-
chanism [45]. This conformational change can also be
evoked by PIP2 [46]. A model has been proposed
whereby Gag bound to RNA through both MA and NC
arrives at the plasma membrane where the presence of
PIP2 and the effect of Gag multimerization displaces the
RNA from the MA region and unleashes the myristic
acid to provide a double anchor to the plasma mem-
brane consisting of both myristate and PIP2 [46].
There is an estimated 5000 Gag proteins in the imma-
ture virion which are reduced to around 1500 in the ma-
ture particle [47], and yet relatively few escort the gRNA
to the budding site. Possibly other nucleic acid molecules
fulfill the gRNA role in masking the highly basic MA
domain and favoring plasma membrane binding over
other cellular membranes in the remainder of the Gag
monomers that congregate there.
The viral budding process
Viral late domains
The essential role of late (L) domains in retrovirus bu-
dding first came to attention from the observation of a
failure to complete budding seen in deletion and muta-
tion of the terminal component of the HIV-1 Gag poly-
protein p6 [1,2]. Two late domains have subsequently
been identified within the p6 region of the HIV-1 Gag:
the PTAP and YPXnL (where X refers any amino acid
and n = 1 ~ 3 residues) motifs (Figure 1B). PTAP was
noted to be conserved in HIV-1 and HIV-2 and other
retroviruses and was later identified in members of
the Filoviridae, Arenaviridae and Hepeviridae families
[48,49] . PTAP-TSG101 interaction was originally iden-
tified by yeast two hybrid studies [50,51]. Functional
analyses of disrupting this interaction by siRNA [50],
mutagenesis [52], or trans dominant inhibition by
TSG101 fragments [53] recapitulates classic phenotype
of L-domain-defective HIV.
Figure 1 (See legend on next page.)
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Figure 1 Diagrammatic overview of the late stages of the HIV life-cycle. (A) After transcription the full length viral RNA is exported from the
nucleus to the cytoplasm for Gag (and Gag-Pol) synthesis. Singly spliced RNA is exported to produce the envelope glycoproteins (dark blue). Gag
binds to a dimeric genomic RNA via its NC domain to form ribonucleoprotein complex which is trafficked to the membrane where more Gag
assembles and budding occurs (black dashed-box and B). During HIV particle assembly or soon after particle release, protease (PR, not shown)
cleaves the Gag polyprotein to MA, CA and NC and protein rearrangement occurs to form the mature virion. (B) Close-up view of the HIV
budding process. ESCRT-I is recruited to the budding site via interactions between PTAP in p6 of Gag and TSG101 of ESCRT-I (black arrow). The
link to ESCRT-III (CHMPs) for budding is via an unknown mechanism but seems to bypass ESCRT-II (black dashed-arrow). Additionally/alternatively,
ALIX binds to YPXnL motif also in p6 and NC via V and Bro1 domain, respectively and directs Gag to ESCRT-III via its Bro1 domain for budding
(blue arrow). RNA involvement in NC-ALIX binding has been suggested (wavy line), but the identity of the RNA is not clear. HIV has no PPXY
motif, but the NEDD4-like ubiquitin ligase family has also been implicated in facilitating HIV joining the ESCRT pathway for budding probably via
adaptors on the plasma membrane (NEDD4-2; red arrow) or the ALIX pathway (NEDD4-1). For membrane scission to occur, ESCRT-III components
are activated and polymerized to form a dome-shaped structure. VPS4, regulated by LIP5-CHMP5 and CHMP1-ISTI binary complexes (not shown),
is recruited to the budding site where it multimerizes to form a dodecamer and disassembles the ESCRT-III filaments for recycling. How
membrane scission occurs is unknown.
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equivalently sited p9 of EIAV (equine infectious anemia
virus) Gag [54] and subsequently in p6 of HIV-1 Gag
[55] and p2b of RSV (Rous sarcoma virus) Gag [56]. It
promotes budding by binding to ALIX (apoptosis-linked
gene 2-interacting protein X), an associated protein of
the ESCRT pathway; although the binding affinity of
ALIX to the YPXnL motif in HIV-1 is lower than to the
corresponding EIAV region [57].
Other retroviruses, including murine leukemia virus
(MLV) [58,59], RSV [60-62], Mason-Pfizer monkey virus
(M-PMV) [63,64], and Human T-cell leukemia/lymphoma
virus type 1 (HTLV-1) [65-67], use a PPXY late domain
(where X refers any amino acid) for virus budding. The
PPXY late domain was first described in the Gag region of
RSV [61] and has since been identified in different virus
family members of the Filoviridae, Arenaviridae and
Rhabdoviridae [48]. These motifs bind to the WW do-
main of NEDD-like HECT ubiquitin ligases [68]. The link
between the PPXY late domain and the ESCRT pathway is
unknown. However, it has been suggested in HIV that
NEDD-like ligase either ubiquitinates and activates
ESCRT-I [69], or interacts with ALIX to function in virus
release [70]. Central to the function of the late domains
are the proteins of the ESCRT pathway.ESCRT proteins
The ESCRT system, first elucidated in yeast [71,72], con-
sists of four sets of different cellular proteins (ESCRT-0, I,
II and III) that are recruited sequentially to endosomal
membranes for biogenesis of MVBs and sorting of the
ubiquitinated cargos into those vesicles [73]. Additionally,
members of ESCRT or ESCRT-associated proteins are
involved in cytokinesis [74], microvesical shedding [75],
exosome biogenesis [76] and ubiquitination-independent
endosomal sorting [77].ESCRT-0
ESCRT-0 comprises two components STAM (signal
transducing adaptor molecule) and HRS (hepatocyte
growth factor (HGF)-regulated tyrosine kinase substrate)
in humans (Vps27 and Hse1 are the homologues in
yeast) and is the least conserved part of the ESCRT
pathway. ESCRT-0 is essential for recognition of ubiqui-
tinated cargos at the endosomal membrane and HRS
interacts with TSG101 of ESCRT-I to cascade the sorting
of cargos and MVB formation. Despite the apparent lack
of requirement of HRS for HIV budding [78], a genome-
wide screen has identified HRS as a host factor required
for HIV infection [79] subsequently confirmed by an
siRNA knockdown study which reduced HIV release to less
than 10% of wild type (wt) levels [80]. The phenotype is dis-
tinct from classic ESCRT related budding defects [50].
Depletion of HRS arrests HIV-1 particles at the cell surface
and in endosomes in a similar manner to that seen in the
BST-2 expressing cells infected with Vpu-defective HIV-1
[81]. Further analysis has shown that HRS is required for
efficient HIV-1 release by facilitating Vpu-induced BST-2
downregulation and degradation [80].
ESCRT-I
ESCRT-I includes TSG101 [50,82], VPS28 [83-85], one
copy of one of the four versions of VPS37 (A-D) [86-88]
and one of the two versions of MVB12 (A&B) [84,89,90]
in a stoichiometry of 1:1:1:1 [84,89,91]. The budding of
HIV requires the intact ESCRT-I, although the involve-
ment of VPS37A and VPS37D in this process have not
been reported. Human ubiquitin associated protein-1
(UBAP-1) is the newly identified member of ESCRT-I
[92] involved solely in ubiquitinated endosomal cargo
degradation but not in HIV budding or midbody abscis-
sion [93,94]. The heterotetrameric complex of ESCRT-I in
yeast consists of a globular headpiece with all four com-
ponents (Vps23, Vps28, Vps37, and Mvb12; orthologs
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humans) attached to an extended stalk composing Vps23,
Vps37 and Mvb12 [84].
The human HRS protein from ESCRT-0 recruits
TSG101 by binding to its UEV (ubiquitin E2 variant) do-
main [78]. Hence it was proposed that Gag could mimic
this TSG101 recruiting ability by directly interacting
with UEV. Indeed structural studies of the UEV domain
in complex with the late domain PTAP motif has shown
the PTAP peptide binds UEV in a bifurcated groove
above the inactive enzymatic site [95]. This was further
supported by the demonstration that a PTAP budding
defect could be rescued when an HRS TSG101 binding
fragment is fused to a PTAP L domain-deleted Gag [78].
Very recently, Nabhan et al. proposed that in order to me-
diate virus budding from host cells HIV Gag (and likely
other viral proteins) alternatively have evolved to mimic
arrestin domain containing protein-1 (ARRDC1)-mediated
ARRDC related microvesicle (ARMMs) release where
both TSG101 and VPS4 (AAA ATPase for disassembling
the ESCRT-III and see below) are required [75]. ARRDC1
is directed to the plasma membrane by its arrestin-
domain and has been previously implicated in functioning
as an adaptor in PPXY-dependent budding [96].
Disruption of VPS28 binding to TSG101 causes the
arrest of HIV budding suggesting VPS28 plays an inte-
gral role in this process [87,97]. The C-terminal domain
of VPS28 binds to the ESCRT-II complex [98], and
fusion of this region to Gag late domain deletion con-
struct rescues an EIAV budding defect [85]. Additionally,
VPS37B and C can rescue a late domain budding defect
when fused to the PTAP late domain deficient Gag, con-
sistent with the notion that VPS37 is also part of
ESCRT-I and involved in virus budding [87,88]. MVB12
appears to be the exception in that the budding process is
not affected when it is depleted [89], but both depletion
and overexpression of MVB12 reduce virus infectivity.
ESCRT-II
ESCRT-II forms as a ‘Y’ shaped heterotetramer including
two copies of Vps25/EAP20, one each of Vps22/EAP30
and Vps36/EAP45 [99]. In yeast, ESCRT-II physically
bridges the ESCRT-I and ESCRT-III complexes and is
essential for MVB protein sorting and vesicle formation
[100-102]. In humans, the interaction between ESCRT-I
and ESCRT-II is slightly different due to the lack of
an NZF (Npl4-type zinc-finger) motif, which forms the
interface in the ESCRT-I/ESCRT-II complex in yeast
[101,103]. The interaction between ESCRT-II and
ESCRT-III, however, is similar to that in yeast [99,100].
Using purified yeast ESCRT components with giant
unilamellar vesicles (GUV), Wollert and Hurley [102]
demonstrated that ESCRT-0 clusters ubiquitinated cargo
on the membrane, and ESCRT-I together with ESCRT-IIdeform the membrane where the cargo is encapsulated.
Both ESCRT-I and II are found on the outside of the
bud where the ESCRT-III is recruited to cleave the bud
to form the intralumenal vesicles. However, a role for
ESCRT-II in HIV budding was not clear until this same
group recently demonstrated that in the GUV system
ESCRT-II is indeed recruited and co-localized with
ESCRT-I on the Gag assembly site [13]. This is in marked
contrast to evidence from siRNA knock down studies
in vivo [12] which suggest that ESCRT-II is dispensable.
This apparent discrepancy is puzzling but may be due to
incomplete protein depletion by siRNA if only a small
amount of ESCRT-II is needed for HIV-1 budding. Alter-
natively there may be some unknown additional pathway
bridging ESCRT-I and -III in vivo.ESCRT-III
The core structure of ESCRT-III includes 12 members
of the charged multivesicular protein (CHMP) family
(CHMP1A, 1B, 2A, 2B, 3, 4A-C, 5, 6, 7 and IST1). Struc-
tural studies of some of the CHMP proteins have shown
that they share an N-terminal 4-helix-bundle core struc-
ture mediating membrane binding and filament for-
mation [104-106]. The C-terminal tail is adapted as in
either auto-inhibition status by folding back on the core
or in an activated position for oligomerization [104,107]
and also contains MIM (MIT (microtubule-interacting
and transport) domain interacting motif ) sequence(s)
that interacts with MIT-containing proteins in a versatile
fashion [108-114]. The involvement of ESCRT-III in
retroviral budding was originally suggested from studies
of a dominant-negative VPS4 which demonstrated a late
domain deficient HIV budding phenotype [50,115]. Later
certain CHMP members were also shown to have similar
effects when overexpressed as fusion isoforms [55,116,117].
More recently, it was shown that introducing certain muta-
tions in the ALIX/CHMP4 binding site can abolish ALIX-
mediated budding [118,119] confirming the integral role of
ESCRT-III during the budding process. Triggering of
ESCRT-III can potentially be achieved by Vps36/EAP45
binding to CHMP6 [117]; VPS28 binding to CHMP6 [85]
or via the associated protein ALIX, which binds to TSG101
and CHMP4 [118,119].
In yeast, Vps20/CHMP6, Snf7/CHMP4, Vps24/CHMP3
and Vps2/CHMP2 are sequentially recruited to the mem-
brane and deform the membrane in vitro [120]. Vps 20
plays an important role in bridging with Vps 25 of ESCRT-II
and triggering the polymerization of Snf7 [121], although
it is not required in HIV budding in vivo [12,122]. ALIX
may provide an alternative route by linking CHMP4 of
ESCRT-III [123]. Alternatively, it is also possible that
other undefined host factor(s) exist that fulfil the link be-
tween Gag and budding.
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CHMP in yeast, in vivo depletion studies in mammalian
cells have shown that only CHMP2 & 4 are involved in
HIV budding [122], although new findings have sug-
gested CHMP3 also plays a synergistic role with CHMP2
[124]. In contrast to those in vivo studies, recent in vitro
reconstitution in GUV using purified ESCRT complex
and HIV Gag has demonstrated that the co-localization
of CHMP4 with Gag is maximal only in the presence of
CHMP6 and other upstream ESCRT complexes implying
the HIV budding route is analogous to that of MVB for-
mation in yeast [13]. Although the exact involvement of
some of the individual CHMP proteins is not yet certain,
CHMP4 in budding formation is confirmed in both
in vitro reconstitution [102,125] and in vivo studies
[122,126].
Once CHMP protein is activated and recruited to the
membrane, it is thought to oligomerize. Indeed, several
studies have demonstrated that CHMP proteins can
form filaments [104,126-129], and it has been hypothe-
sized that the formation of such filament would deform
the membrane. This, together with oligomerized and
activated VPS4, may ultimately provide sufficient force
for scission to occur, although VPS4 independent bud-
ding is also documented [102,125]. Interestingly, obser-
vation of such polymerized CHMP proteins in vivo has
largely been unsuccessful apart from overexpression of
CHMP4 [126] and CHMP2B [129].
Vta1/LIP5, Did2/CHMP1, Ist1/IST1 and Vps60/CHMP5
regulate and recruit VPS4 to the budding site [107,130-135].
VPS4 exists as a single isoform in yeast but is present as
two isoforms in humans (VPS4/SKD1A&B) [136]. It con-
tains an N-terminal MIT domain, a link segment and a
single ATPase cassette. MIT domain binds to MIM1
[109,113] and MIM2 [108,110] of subset of CHMP pro-
teins and both MIM1&2 binding sites are required for
recruiting VPS4A to endosomal membrane and VPS4B
for HIV budding [108]. VPS4 exists as a catalytically in-
active dimeric form in the cytoplasm but once recruited
to the membrane-associated ESCRT-III, it forms a cataly-
tically active dodecamer [115,137]. ESCRT-associated pro-
tein LIP5 is believed to play an important regulatory role in
VPS4 oligomerization [138]. It functions by bridging VPS4
through VSL (Vta1/SBP1/LIP5) domain and ESCRT-III by
its tandem MIT domains located at the N terminus
[111,138,139]. Given the regulatory role of LIP5 in VPS4
oligomerization, it is probably not surprising that deple-
tion of LIP5 also decreased HIV budding [134]. The for-
mation of dodecamer complexes of VPS4 disassemble
ESCRT-III through an ATP-driven process which is
poorly defined. However, from the nature of VPS4 as an
AAA-type ATPase, it has been suggested that ESCRT-III
is engaged by passing through the central pole of VPS4
dodecamers [140,141].Investigation of how membrane scission occurs is still
an area of great interest. Several schools of thoughts
exist. One model suggests that the depolymerization on
ESCRT-III filaments by VPS4 provides enough force to
the underlying membrane for scission to occur [120]. It
has been shown microscopically that VPS4 is recruited
to the membrane abscission site during cytokinesis [142]
and retrovirus budding [143,144] before the cleavage
occurs supporting the notion that VPS4 may provide the
constriction for membrane scission. However, VPS4 in-
dependent membrane scission has also been observed
in vitro [102,125]. Other membrane scission models
have also been proposed. Based on the observations that
various members of ESCRT-III can form a filamentous
structure in vitro [104,127,128] and in vivo [126,129], it
was proposed that the progression of this filament would
lead to thinning of the plasma membrane and to a cer-
tain degree the energy accumulated would favor fission
[145]. Recent studies have suggested that CHMP4
polymerization is regulated by CC2D1A and CC2D1B
since when CC2D1A is overexpressed HIV budding is
inhibited and conversely if CC2D1 is depleted HIV bud-
ding is enhanced [146,147]. A further alternative has re-
cently been proposed suggesting that individual ESCRT-III
filaments are sufficient to promote the scission [148]. This
model is based on the observation that Vps32/CHMP4 is
recruited by ESCRT-II and the Vps20/CHMP6 complex to
the curvature region of the membrane and as such modu-
lates the mobility of the membrane. It was proposed that
when the binding energy between ESCRT-III filament and
membrane exceeds the energy barrier to scission, vesicles
would more likely to be pinched off from the membrane.
ALIX
ALIX is a mammalian homologue of Bro1 in yeast, origi-
nally identified as a member of class E VPS class genes
from yeast [149]. Subsequently, HIV has also been shown
to be able to utilize ALIX to bud from the cells, although
this pathway appears to be subordinate to the ESCRT-I
route [118,150]. Unlike the classical ESCRT pathway
where ESCRT-I and -III in conjunction with a PTAP late
domain are involved in virus budding, ALIX-mediated
budding relies on the interaction with a different late
domain, YPXnL, which is also located within the p6 region
of Gag in HIV-1. No YPXnL-domain-containing cellular
proteins had been identified in vivo until recently when it
was shown that ALIX binds to syntenin, functioning in
exosome biogenesis [76] and protease-activated receptor 1
(PAR1) for ubiquitination-independent endosomal cargo
sorting [77].
ALIX contains an effector V domain for binding to the
YPXnL motif [118,151] and polyubiquitin [152]. This is
flanked by an N terminus Bro1 domain and a proline-
rich C-terminal domain (PRD). The PRD also binds to
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though both monomers and dimers were seen [118,155],
the active conformation of ALIX is a dimer [123,156,157].
The ALIX pathway was first discovered in studies using a
Gag that lacked a functional TSG101-binding site
[55,117]. It was shown that, when overexpressed, ALIX
rescued the budding defect and this rescue is fully
dependent on the YPXnL late domain [118,119] and intact
polyubiquitin binding sites on V domain [152]. In addition,
structural and biochemical analyses of an ALIX homologue
in yeast [158] or ALIX itself [118,119,159] have shown that
mutating some residues in the hydrophobic patch of Bro 1
domain abolishes its interaction with CHMP4 and as such
eliminates its ability to rescue the budding defect. Interes-
tingly, when overexpressed, Bro 1 rescues the release of
HIV-1 lacking both PTAP and YPXnL motifs [160]. Func-
tional analysis has shown that ALIX mediated rescue also
requires the NC domain in Gag [160,161]. The interaction
between ALIX and the NC domain was documented as
being insensitive to benzonase [161], a powerful nuclease.
However, very recent data suggest that the interaction
between the NC domain of Gag and the Bro1 domain of
ALIX is RNA dependent [11], although there was no evi-
dence that it was specific for viral RNA. If the latter is
validated it would in part answer the question as to the
involvement of RNA in this stage of the assembly process.
The C-terminal PRD domain is also essential for rescuing
ALIX mediated virus budding, although the binding sites
with TSG101, endophilin, CIN85 and CMS are dispens-
able for the function of ALIX in HIV-1 budding [118,119].
The PRD domain also regulates the ALIX function by
folding back against the upper domains and as such auto-
inhibits YPXnL late domain binding site on the V domain
[157,162,163].
NEDD4-like ubiquitin ligases
There are several members of the NEDD-like ubiquitin
ligase family. They all contain an N terminus C2 domain
for membrane binding [164], two to four WW (Trp-Trp)
substrate-binding domains and a C-terminal HECT (hom-
ologous with the E6-associated protein C-terminus) cata-
lytic domain for targeting ubiquitination. The PPXY late
domain was first described in the Gag protein of RSV
[60,62], which functions by binding to the WW domain of
NEDD-like HECT ubiquitin ligases. Despite the lack of a
PPXY late domain in HIV-1, overexpression of NEDD4-1
or 4-2 nevertheless stimulates the PTAP late domain
mutant defective budding [69,70]. Interestingly, the most
potent effector in rescuing the budding defect is NEDD4-
2s/ΔC2 [165], a natural isoform of NEDD4-2 in which
most of the C2 domain is truncated [166]. Additionally,
neither the PTAP nor the YPXnL domain is required for
NEDD4-2s mediated budding [69,165]. To confer a rescue
effect, NEDD4-2s must be catalytically active suggestingubiquitination of viral or cellular proteins is needed
[69,165]. The remaining C2 domain is also important in
binding to Gag and itself is sufficient to confer HIV-1
budding ability on various members of NEDD family
[167]. Depletion of TSG101 abrogates the NEDD4-2s
mediated remediation of budding defect, suggesting that
ESCRT-I is recruited in this process [69]. Like NEDD4-2,
NEDD4-1 can also rescue the PTAP late domain budding
defect, albeit less efficiently than NEDD4-2 [69,70]. Addi-
tionally, the effect of NEDD4-1 on budding functions in a
different manner that is independent of cellular TSG101
and requires the YPXnL late domain. This implies that
ALIX recruits NEDD4-1 to mediate HIV budding through
the YPXnL-ALIX budding pathway [70].
Post budding Gag processing
Formation of the budded particle and final scission from
the cell is associated with the processes of proteolytic
processing of the Gag polyprotein into its component
fragments, morphogenesis of the spherical particle into
the MA lined enveloped virion with the conical core and
maturation of the loosely associated paired RNA ge-
nomes into a mature tightly linked dimer. Genomic
RNA has been suggested in the past to have a structural
scaffolding role aiding viral assembly [6,168,169] and
even trace amounts of nucleic acid appear to enhance
in vitro assembly. Gag dimerization has been implicated
as an important first step [170,171]. Mutations that dis-
rupt the dimer interface between the CA domains pre-
vent correct assembly [172]; a plausible role for the
gRNA is that it also helps to bridge Gag dimers [173].
The MA and CA domains of Gag foster formation of
hexameric arrays of the polyprotein but during cleavage
the N-terminal domain of CA can form both pentamers
and hexamers and it is this that generates the steric ca-
pability to form the asymmetric fullerene cone of the
mature capsid [7,174-176].
Release of the homodimeric aspartyl protease (PRO)
from Gag/Pol is initiated in an as yet obscure manner al-
though there is evidence for the involvement of clathrin
[177,178], but once this has begun autocatalytic cleavage
of the remaining Gag and Gag/Pol proteins can occur.
Proteolytic cleavage of the Gag and Gag/Pol polyproteins
by the viral protease is associated with an alteration in
the nature of the dimer interaction from rather loosely
associated molecules to a tight dimer. It has become ap-
parent that all these processes are closely interconnected
[179-181]. In HIV-2, it has been shown that the proteo-
lytic cleavage of Gag and the packaging of dimeric RNA
are intimately inter-dependent [180]; failure of RNA
dimerization leads to aberrant proteolytic cleavage of
Gag. The reason for this is not clear but it may be due
to the lack of an RNA scaffold in bringing together two
protease monomers within two Gag/Pol polyproteins
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Conversely, it has been known for a considerable time
that a protease deficient HIV produces poorly dimeric
RNA genomes [23] and the mis-processing of HIV-2 Gag
was shown to correct in long-term culture by reversion
mutation in the MA portion of Gag and this unexpectedly,
despite the persistence of the RNA dimer mutation, led to
a return of packaging wt levels of dimeric RNA [180]. Si-
milar reversion mutations in the HIV-1 Gag have been
seen which restore replication to dimer mutants [182] al-
though the analysis did not reveal whether the RNA
dimerization mutation had been left unchanged or RNA
dimer packaging had been restored.
Conclusions
Despite remarkable progress in understanding this
intimate interaction between the virus and the cell in
which results in viral egress, the late stage of the viral
life cycle is still a patchwork of areas of better and less
well understood steps. At present it resembles a jigsaw
puzzle with missing pieces. The central process of
ESCRT mediated budding is fairly well established, but
there are still controversies; and the significance of the
recently identified variants of some of the ESCRT com-
ponents is still unclear. The roles of gRNA, in assem-
bling what is primarily a nucleoprotein complex, are
only just beginning to be understood. There are gaps in
our understanding of the connection of gRNA capture
to budding although interdependencies between RNA and
protein processing are beginning to emerge. Understand-
ing the assembly process is critically important not least
because the diverse interactions with cellular components
are promising drug targets since the scope for viral muta-
tional escape is limited due to the unchanging nature of
the essential cellular factors involved. More work is
needed to fill in the missing links in this remarkable
process and to identify susceptible areas for therapeutic
intervention.
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